{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:42:12Z","timestamp":1761093732407,"version":"build-2065373602"},"reference-count":11,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1016\/j.bcmd.2012.01.005","type":"journal-article","created":{"date-parts":[[2012,2,10]],"date-time":"2012-02-10T02:25:35Z","timestamp":1328840735000},"page":"199-201","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Effects of the novel aurora kinase\/JAK inhibitor, AT9283 and imatinib on Philadelphia positive cells in vitro"],"prefix":"10.1016","volume":"48","author":[{"given":"Mohsin","family":"Shah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Gallipoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Lyons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tessa","family":"Holyoake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"J\u00f8rgensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2012.01.005_bb0005","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1182\/blood-2006-08-040022","article-title":"Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR\/ABL+ progenitors via JAK-2\/STAT-5 pathway activation","volume":"109","author":"Wang","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2012.01.005_bb0010","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/leu.2009.299","article-title":"Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors","volume":"24","author":"Hiwase","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.bcmd.2012.01.005_bb0015","first-page":"1442","article-title":"AT-9283, a small-molecule multi-targeted kinase inhibitor for the potential treatment of cancer","volume":"11","author":"Kimura","year":"2010","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.bcmd.2012.01.005_bb0020","article-title":"A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies","author":"Arkenau","year":"2011","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bcmd.2012.01.005_bb0025","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/stem.5530010205","article-title":"Establishment of a Ph1 chromosome-positive cell line from chronic myelogenous leukemia in blast crisis","volume":"1","author":"Kubonishi","year":"1983","journal-title":"Int. J. Cell Cloning"},{"key":"10.1016\/j.bcmd.2012.01.005_bb0030","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3109\/08977194.2011.614949","article-title":"JAKs go nuclear: emerging role of nuclear JAK1 and JAK2 in gene expression and cell growth","volume":"29","author":"Zouein","year":"2011","journal-title":"Growth Factors"},{"key":"10.1016\/j.bcmd.2012.01.005_bb0035","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/84683","article-title":"Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase","volume":"7","author":"Vigneri","year":"2001","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcmd.2012.01.005_bb0040","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2012.01.005_bb0045","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1182\/blood-2009-03-211466","article-title":"Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells","volume":"116","author":"Tanaka","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2012.01.005_bb0050","first-page":"1501","article-title":"Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival","volume":"116","author":"Hamilton","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2012.01.005_bb0055","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity","volume":"121","author":"Corbin","year":"2011","journal-title":"J. Clin. Invest."}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107997961200006X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107997961200006X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:28:39Z","timestamp":1761049719000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S107997961200006X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":11,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S107997961200006X"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2012.01.005","relation":{},"ISSN":["1079-9796"],"issn-type":[{"type":"print","value":"1079-9796"}],"subject":[],"published":{"date-parts":[[2012,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of the novel aurora kinase\/JAK inhibitor, AT9283 and imatinib on Philadelphia positive cells in vitro","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2012.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}